Johnson & Johnson
4Q Revenues: $21.4 billion (+7%)
4Q Earnings: $4.1 billion (+28%)
FY Revenues: $85.2 billion (+6.5)
FY Earnings: $13.3 billion (-18.6%)
Comments: Innovative Medicine worldwide operational sales grew 5% in the quarter. Growth was driven by DARZALEX (daratumumab) with sales up 22% to $2.6 billion, ERLEADA (apalutamide) with sales up 20% to $647 million, TECVAYLI (teclistamab-cqyv) in Other Oncology, and CARVYKTI (ciltacabtagene autoleucel) with sales of $159 million. STELARA (ustekinumab) sales were $2.75 million, up 15%. TREMFYA (guselkumab) sales were $910 million, up 21%. SPRAVATO (esketamine) sales were $206 million, up 74%. Growth was partially offset by ZYTIGA (abiraterone acetate) with sales down 26% to $201 million, and IMBRUVICA (ibrutinib) with sales down 9% to $788 million, and REMICADE (infliximab) sales down 10% to $429 million. COVID-19 Vaccine sales were down 94% to $44 million.